Tenofovir alafenamide: safer, but questions remain

Lancet HIV. 2016 Apr;3(4):e148-9. doi: 10.1016/S2352-3018(16)00039-4. Epub 2016 Mar 14.

Authors

Mark A Boyd¹, David A Cooper²

Affiliations

¹ The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia. Electronic address: mboyd@kirby.unsw.edu.au.
² The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia.

PMID: 27036985
DOI: 10.1016/S2352-3018(16)00039-4

No abstract available

Publication types

Comment

MeSH terms

Adenine / therapeutic use
Anti-HIV Agents / therapeutic use*
Antiviral Agents / therapeutic use
HIV Infections / drug therapy
HIV-1
Humans
Organophosphonates / therapeutic use
Tenofovir*

Substances

Anti-HIV Agents
Antiviral Agents
Organophosphonates
Tenofovir
Adenine